Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Mr Iwasaki to Improve Labor-Management Relations via Dialogue: Pfizer Japan
April 17, 2006
- SEMINAR
April 17, 2006
- Kowa, Nikken's Integration Plan Accredited
April 17, 2006
- Sawai Expands Business with Wholesalers, Dispensing Pharmacies
April 17, 2006
- BUSINESS NEWS IN BRIEF
April 17, 2006
- GENERIC NEWS IN BRIEF
April 17, 2006
- Council to Collect Evidence on Pediatric Use of 5 Drugs
April 17, 2006
- Astellas Switches to Disease-Based 2-Line Marketing System
April 10, 2006
- SELF-MEDICATION NEWS IN BRIEF
April 10, 2006
- Deloitte Touche Tohmatsu Forms "Pharma Team" to Support Life Science Industry
April 10, 2006
- OPINION
April 10, 2006
- Janssen Pharm. Reports 7th Year of Double-Digit Growth
April 10, 2006
- HUMAN RESOURCES NEWS IN BRIEF
April 10, 2006
- Yoh Narimatsu Appointed President and CEO of Quintiles Japan
April 10, 2006
- MEDICAL DEVICE NEWS IN BRIEF
April 10, 2006
- BUSINESS NEWS IN BRIEF
April 10, 2006
- JMA
April 10, 2006
- FY2006 Budget Proposal Approved
April 10, 2006
- 39 of World's 99 Top-Selling Drugs Unapproved in Japan: Mr Wolf of PhRMA
April 10, 2006
- Korosho to Gear Up Steps to Eliminate Provisional Delivery
April 10, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…